3 completed, 3 unknown, 2 recruiting, 1 terminated. 10 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 3, Unknown 3, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Intestinal Polyposis: new trials by email Literature Review of Intestinal Polyposis trials Research Report on Intestinal Polyposis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis eRapa (encapsulated rapamycin), Placebo - Familial Adenomatous Polyposis (FAP) | Phase 3 | Recruiting | Rapamycin Holdings Inc. | 168 | 2025-07-18 | 2026-06-02 |
| Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis celecoxib monotherapy, celecoxib and metformin combination - Familial Adenomatous Polyposis | Phase 3 | Unknown | Yonsei University | 28 | 2024-08-13 | 2024-08-09 |
| Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis Eicosapentaenoic acid free fatty acid (EPA-FFA), Placebo - Familial Adenomatous Polyposis | Phase 3 | Unknown | S.L.A. Pharma AG | 204 | 2018-12-05 | 2024-04-25 |
| The Cancer of the Pancreas Screening-5 CAPS5)Study Secretin, MRI, Tumor marker gene test with CA19-9 - Pancreas Cancer, Peutz-Jeghers Syndrome (PJS) | Phase 3 | Recruiting | Johns Hopkins University | 9000 | 2014-01-06 | 2026-10-22 |
| Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis | Phase 3 | Completed | Cancer Prevention Pharmaceuticals, Inc. | 171 | 2013-10-01 | 2021-06-08 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 37 | 2009-05-01 | 2013-05-16 |
| Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 58 | 2006-11-01 | 2014-08-22 |
| Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Celecoxib, Placebo - Adenomatous Polyposis Coli | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 106 | 2006-09-01 | 2021-02-21 |
| Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Ursodeoxycholic acid, Placebo - Adenomatous Polyposis Coli, Familial | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 90 | 2004-10-01 | 2009-07-29 |
Adenomatous Polyposis Coli (9) · Polyps (4) · Adenoma (2) · Adenomatous Polyps (1) · Breast Neoplasms (1) · Colonic Polyps (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Duodenal Neoplasms (1) · Dysplastic Nevus Syndrome (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Colonic Diseases (10) · Colorectal Neoplasms (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Genetic Diseases, Inborn (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Neoplasms, Glandular and Epithelial (9)
Celecoxib (3) · Eflornithine (2) · Sulindac (2) · Ursodeoxycholic Acid (2) · CA-19-9 Antigen (1) · Docosahexaenoic Acids (1) · Eicosapentaenoic Acid (1) · Endoscopy (1) · Secretin (1)
Cancer Prevention Pharmaceuticals, Inc. (2) · S.L.A. Pharma AG (2) · Assistance Publique - Hôpitaux de Paris (1) · Johns Hopkins University (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Radboud University Medical Center (1) · Rapamycin Holdings Inc. (1) · Yonsei University (1)
United States (4) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Germany (2) · Puerto Rico (2) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Hong Kong (1) · Hungary (1) · Israel (1)
Alfred M. Cohen, M.D. (1) · Bjorn WH van Heumen, MD (1) · Carol Burke, M.D. (1) · Ellen Kampman, Ph D (1) · Fokko M Nagengast, MD, Ph D (1) · Gary Shangold, MD (1) · James Church, M.D. (1) · Luigi Ricciardiello, MD (1) · Michael Goggins, MD (1) · Nicholas J West, MB BS FRCS (1) · Wilbert HM Peters, Ph D (1) · Yann RA Parc, M.D., Ph.D. (1)
PMID 20348368, PMID 21899713, PMID 23919274, PMID 24245549, PMID 31197699, PMID 31676359, PMID 32905675, PMID 33161160, PMID 34149034, PMID 34261858
R01CA176828 (1), U01CA210170 (1)